Drugs / TGF Beta 3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07137130 | Feb → May 2026 overdue | hyperpigmentation of the skin | Indonesia University | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGF Beta 3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07137130 ↗ |
| Known as | TGF-β3 | “Moon et al. examined the effects of TGF-β3 on melanogenesis in human melanocytes co-cultured with skin cells irradiated with ultraviolet (UV) light, and in UV-irradiated human skin.” NCT07137130 ↗ |
| Action | Inhibit | “TGF-β3 inhibits melanogenesis by inhibiting MITF expression” NCT07137130 ↗ |
| Route | Other | “Group B, the treatment group, used Secretome (raw material) 3ml with addition of TGF Beta 3 Intradermal injection” NCT07137130 ↗ |
| Target | MITF | “TGF-β3 inhibits melanogenesis by inhibiting MITF expression” NCT07137130 ↗ |